VEGFA and age-related macular degeneration: As a consequence of the invasiveness and apparent toxicity associated with repetitive intra-ocular injection of anti-VEGF agents, there is a clear need to develop a long-term, single use treatment for AMD that allows for tight temporal control of anti-VEGF expression.